Disease · MONDO_0005311
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Obicetrapib 10mg vs Placebo: deaths from any cause | 19 of 1,685 | 12 of 843 | 2,528 | NCT05142722 | Trial comparisons |
| Obicetrapib 10mg vs Placebo: serious adverse events | 211 of 1,685 | 117 of 843 | 2,528 | NCT05142722 | Trial comparisons |
Glipizide (GLP) 5 mg vs Rosiglitazone (RSG) 4 mg: Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for All-cause Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularization, or Hospitalization for Recurrent Myocardial Ischemia (MACE Composite 1) | 38 of 337 | 39 of 331 | 668 | NCT00116831 | Trial comparisons |
Glipizide (GLP) 5 mg vs Rosiglitazone (RSG) 4 mg: Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (MACE Composite 2) | 10 of 337 | 14 of 331 | 668 | NCT00116831 | Trial comparisons |
| Glipizide (GLP) 5 mg vs Rosiglitazone (RSG) 4 mg: serious adverse events | 71 of 337 | 71 of 331 | 668 | NCT00116831 | Trial comparisons |
| 17B-estradiol vs Placebo: deaths from any cause | 1 of 323 | 1 of 320 | 643 | NCT00114517 | Trial comparisons |
| 17B-estradiol vs Placebo: serious adverse events | 43 of 323 | 45 of 320 | 643 | NCT00114517 | Trial comparisons |
| Inclisiran vs Inclisiran + BS: Number of Participants Interviewed for CFIR Analysis. | 28 of 297 | 28 of 297 | 594 | NCT04807400 | Trial comparisons |
| Rosuvastatin 20 mg vs Placebo: deaths from any cause | 0 of 272 | 1 of 268 | 540 | NCT02546323 | Trial comparisons |
| Rosuvastatin 20 mg vs Placebo: serious adverse events | 38 of 272 | 34 of 268 | 540 | NCT02546323 | Trial comparisons |
| Metformin vs Placebo: deaths from any cause | 5 of 219 | 2 of 209 | 428 | NCT01483560 | Trial comparisons |
| Metformin vs Placebo: serious adverse events | 34 of 219 | 31 of 209 | 428 | NCT01483560 | Trial comparisons |
| ACZ885 150mg vs Placebo: serious adverse events | 25 of 95 | 14 of 94 | 189 | NCT00995930 | Trial comparisons |
| Polypill vs Usual Care: deaths from any cause | 5 of 74 | 2 of 74 | 148 | NCT03329599 | Trial comparisons |
| Polypill vs Usual Care: serious adverse events | 3 of 74 | 0 of 74 | 148 | NCT03329599 | Trial comparisons |
| Valsartan vs Placebo: serious adverse events | 3 of 80 | 0 of 40 | 120 | NCT00208767 | Trial comparisons |
| Chloroquine Subjects vs Placebo Subjects: deaths from any cause | 0 of 59 | 0 of 57 | 116 | NCT00455403 | Trial comparisons |
| Chloroquine Subjects vs Placebo Subjects: serious adverse events | 5 of 59 | 2 of 57 | 116 | NCT00455403 | Trial comparisons |
| Salsalate vs Placebo: deaths from any cause | 0 of 58 | 0 of 58 | 116 | NCT00760019 | Trial comparisons |
| Salsalate vs Placebo: serious adverse events | 0 of 58 | 0 of 58 | 116 | NCT00760019 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005311/comparisons